Enlivex Therapeutics Ltd. Quarterly Retained Earnings (Accumulated Deficit) in USD from Q4 2013 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Enlivex Therapeutics Ltd. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q4 2013 to Q2 2024.
  • Enlivex Therapeutics Ltd. Retained Earnings (Accumulated Deficit) for the quarter ending June 30, 2024 was -$119M, a 23% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 -$119M -$22.3M -23% Jun 30, 2024 6-K 2024-08-30
Q4 2023 -$112M -$29.1M -35% Dec 31, 2023 6-K 2024-08-30
Q2 2023 -$97M -$26.9M -38.4% Jun 30, 2023 6-K 2023-09-01
Q4 2022 -$83M -$31.1M -59.8% Dec 31, 2022 20-F 2024-04-30
Q2 2022 -$70.1M -$26.3M -60% Jun 30, 2022 6-K 2022-08-22
Q4 2021 -$52M -$14.5M -38.6% Dec 31, 2021 20-F 2023-04-10
Q2 2021 -$43.8M -$14.3M -48.5% Jun 30, 2021 6-K 2021-08-06
Q4 2020 -$37.5M -$11.8M -46.1% Dec 31, 2020 20-F 2022-04-29
Q2 2020 -$29.5M Jun 30, 2020 6-K/A 2020-10-13
Q4 2019 -$25.7M -$9.38M -57.6% Dec 31, 2019 20-F 2021-04-30
Q4 2018 -$16.3M +$29.5M +64.4% Dec 31, 2018 20-F 2020-04-30
Q4 2017 -$45.8M -$5.95M -14.9% Dec 31, 2017 20-F/A 2020-01-23
Q4 2016 -$39.8M -$16M -67.4% Dec 31, 2016 20-F 2018-04-23
Q4 2015 -$23.8M -$15.4M -182% Dec 31, 2015 20-F 2017-02-24
Q4 2014 -$8.42M -$7.02M -502% Dec 31, 2014 20-F 2016-03-29
Q4 2013 -$1.4M Dec 31, 2013 20-F 2015-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.